An individual walks by a CVS pharmacy retailer in Manhattan, New York, U.S., November 15, 2021.
Andrew Kelly | Reuters
CVS Health on Tuesday mentioned it will revamp how it prices prescription drugs and scrap a posh model that sometimes units how a lot pharmacies get reimbursed and what sufferers pay for these drugs.
The new effort makes CVS the most recent firm to attempt to upend the normal prescription drug pricing system, which has confronted years of political scrutiny for what critics name an absence of transparency and inflated health-care prices for U.S. customers.
CVS will launch a new model for reimbursing its pharmacies on Jan. 1, 2025, executives mentioned through the firm’s 2023 investor day.
CVS’ new model may change the price of prescription drugs for some sufferers, however it won’t essentially make all drugs price much less, firm executives mentioned. Some drugs might price much less, whereas prices of others may rise, they famous. But extra prescription prices ought to fall than climb for customers, employers and well being insurers, in accordance to the executives.
“This is a extremely foundational step in the direction of a clear model for customers, and it units the stage for payers to create extra predictable pricing on the pharmacy counter,” mentioned Prem Shah, president of CVS’ pharmacy and client wellness phase, through the firm’s investor day.
CVS mentioned the plan, named CVS CostVantage, will use a “sustainable and clear” components to decide a drugs’s worth and the corresponding reimbursement pharmacies obtain from pharmacy profit managers. Those middlemen negotiate drug reductions with producers on behalf of well being insurers, giant employers and others that contract them.
Under the new model, CVS’ greater than 9,000 retail pharmacies will get reimbursed by PBMs and different payors primarily based on the price of the drug, a “clearly outlined” markup, and a charge to cowl dealing with and dishing out the prescriptions, in accordance to Shah.
Currently, pharmacies are sometimes paid utilizing a sophisticated system indirectly primarily based on what they spent to buy drugs. That model, which includes a multitiered community of insurers, drug producers, PBMs and pharmacies, leads to ambiguity round charges and markups added to the unique price of a drug.
Billionaire Mark Cuban final 12 months launched a web-based pharmacy that takes an identical method to CVS’ new reimbursement model. The firm, referred to as Cost Plus Drugs, goals to drive down the worth of medicines broadly by promoting them at a set 15% markup over their price, plus pharmacy charges.
Cuban’s enterprise is already shaking up the broader health-care trade: CVS suffered a blow over the summer time when a serious California well being insurer, Blue Shield of California, announced it will no longer use the company as its PBM and as an alternative will accomplice with a number of firms, together with Cuban’s agency and Amazon Pharmacy.
CVS Health’s Caremark is among the main PBMs within the U.S. Caremark and different PBMs have confronted elevated scrutiny over their function in surging drug prices, and the Federal Trade Commission can be investigating their practices.
Cuban’s drug firm has put stress on different firms that handle drug advantages to make their very own modifications. For instance, Cigna introduced final month that its PBM will offer a pricing model similar to Cost Plus Drugs.
The Biden administration is taking its personal steps to rein in prices of medicines.
As a part of the president’s Inflation Reduction Act, the administration in August introduced the first 10 prescription drugs that will likely be topic to drug worth negotiations with the federal Medicare program, which goals to make expensive drugs extra reasonably priced for older Americans.
Don’t miss these tales from CNBC PRO: